GlassScriptPhysician profile
Alejandra Vega
NPI 1710419759
$2,886.37
in general payments reported to CMS, 2019-2025
32 companies · $920 in 2025
The $920 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $548 · 2023: $588 · 2024: $511 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886 · Travel and Lodging: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.58 |
| Travel and Lodging | $133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $305.90 | 2021-2024 | Liletta, Orilissa, Lo Loestrin Fe |
| Hologic Sales and Service, LLC | $298.59 | 2023-2025 | Acessa Provu System, Sonata Sonography-Guided Transcervical Fibroid Ablation System, Aptima |
| Evofem Biosciences, INC. | $253.88 | 2021-2025 | Phexxi, Phexx, Solosec |
| Exeltis, USA INC. | $221.25 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $185.09 | 2023-2024 | Myfembree |
| Mayne Pharma Commercial LLC | $170.32 | 2021-2024 | |
| Myovant Sciences INC. | $148.05 | 2022 | |
| Sage Therapeutics, LLC | $139.76 | 2024-2025 | Zurzuvae |
| Intuitive Surgical, INC. | $137.96 | 2025 | |
| Medtronic, INC. | $134.75 | 2023-2025 | Ligasure, V-Loc 180 |
| Organon LLC | $118.20 | 2021-2024 | Nexplanon |
| Octapharma USA, INC. | $105.33 | 2025 | Fibryga |
| Bayer Healthcare Pharmaceuticals INC. | $86.22 | 2022-2023 | |
| Exact Sciences Corporation | $85.91 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $83.14 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $52.70 | 2021-2025 | Ally II Ups, Endosee |
| Optumhealth Care Solutions, LLC | $44.29 | 2023-2025 | Eitan Medical, Vivify Health Care Team Portal 001, Vivify Health Care Team Portal |
| Therapeuticsmd, INC. | $30.22 | 2021-2022 | |
| Astellas Pharma US INC | $28.12 | 2025 | Veozah |
| Ethicon US, LLC | $27.42 | 2025 | Stratafix, Dermabond, Ethicon |
| Avion Pharmaceuticals | $26.24 | 2021-2022 | |
| Lilly USA, LLC | $24.73 | 2023 | Zepbound |
| Dexcom, INC. | $24.03 | 2025 | Dexcom G6 Transmitter |
| Innovation Technologies INC | $22.36 | 2024 | Irrisept |
| Millicent US INC | $21.40 | 2023 | Intrarosa |
| Agile Therapeutics, INC. | $18.24 | 2023 | Twirla |
| Novo Nordisk INC | $17.25 | 2024 | Wegovy |
| Daiichi Sankyo INC. | $17.17 | 2023 | Injectafer |
| Lupin INC. | $15.53 | 2021 | |
| Amgen INC. | $15.43 | 2021 | |
| Dysis Medical, INC. | $14.86 | 2022 | |
| Scynexis, INC. | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandra Vega listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.